For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide isolated from the polypeptide neuroprotective drug Cortexin and developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is the most clinically supported Khavinson bioregulator other than Pancragen: oral administration in 72 patients with traumatic brain injury consequences (0.2 mg twice daily, 20 to 30 days, with a 37-patient control group) produced improvements in memory, headache reduction, emotional stability, and EEG alpha-index changes. Additional published rodent data include prenatal neuroprotection, hypoxia tolerance, cognitive improvement across aging models, and dendritic spine preservation in Alzheimer's and Huntington's disease cell models. The 2021 MDPI Molecules open-access review provides the most comprehensive mechanistic characterization to date. No randomized controlled trial has been published.
The complete Pinealon profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use